My­ovan­t's re­l­u­golix clears first uter­ine fi­broids PhI­II test, but com­pe­ti­tion from Ab­b­Vie/Neu­ro­crine makes in­vestors jit­tery

Vivek Ra­maswamy’s bet on Take­da’s re­l­u­golix has worked — sort of.

Less than three years af­ter the pro­lif­ic deal­mak­er spawned My­ovant as part of his um­brel­la …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER